Over the past decade, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as highly effective agents for reducing both blood glucose levels and body weight in individuals with type 2 diabetes (T2D), obesity, or both [21,22,23,24,25,26,27,28]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.